Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Sheldon Greer"'
Autor:
Martina L. Veigl, Long Shan Li, David A. Boothman, Mark C. Wagner, David Sedwick, Julio C. Morales, Sheldon Greer, Mark Meyers, Richard Fishel
Publikováno v:
British Journal of Pharmacology. 158:679-692
The metabolism and efficacy of 5-fluorouracil (FUra) and other fluorinated pyrimidine (FP) derivatives have been intensively investigated for over fifty years. FUra and its antimetabolites can be incorporated at RNA- and DNA-levels, with RNA level in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7309febb2826889948abe4edecfea52
https://doi.org/10.1111/j.1476-5381.2009.00423.x
https://doi.org/10.1111/j.1476-5381.2009.00423.x
Autor:
Ronald Burk, Sheldon Greer, Alex Aller, Anna Knapinska, Marcy Alvarez, Michael Dauphinée, David Arnold, Christina Norris, Chandra Wozniak, Marisol Mas
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 51:791-806
Purpose: The study's goals were as follows: ( 1 ) to extend our past findings with rodent tumors to human tumors in nude mice, ( 2 ) to determine if the drug protocol could be simplified so that only CldC and one modulator, tetrahydrouridine (H 4 U),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a0dd6781eaf38839d59f16bc5719a5f
https://doi.org/10.1016/s0360-3016(01)01706-0
https://doi.org/10.1016/s0360-3016(01)01706-0
Autor:
Long Shan, Li, Julio C, Morales, Martina, Veigl, David, Sedwick, Sheldon, Greer, Mark, Meyers, Mark, Wagner, Richard, Fishel, David A, Boothman
Publikováno v:
British journal of pharmacology. 158(3)
The metabolism and efficacy of 5-fluorouracil (FUra) and other fluorinated pyrimidine (FP) derivatives have been intensively investigated for over fifty years. FUra and its antimetabolites can be incorporated at RNA- and DNA-levels, with RNA level in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e8162683b40135eba92c45bf488f4bd6
https://pubmed.ncbi.nlm.nih.gov/19775280
https://pubmed.ncbi.nlm.nih.gov/19775280
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 19:357-365
Bolus doses of 5-chlorodeoxycytidine (CldC) administered with modulators of pyrimidine metabolism, followed by X-irradiation, resulted in a 2-fold dose increase effect against RIF-1 tumors in C3H mice. Pool size studies of the fate of [ 14 -C]-CldC i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8942e0439220ac4db721ebb2100703be
https://doi.org/10.1016/0360-3016(90)90544-t
https://doi.org/10.1016/0360-3016(90)90544-t
Autor:
Victor E. Marquez, Peter A. Jones, Christine B. Yoo, Daniel J. Weisenberger, Jody C. Chuang, Chandra Wozniak, Torben F. Ørntoft, Thomas Thykjaer, Gangning Liang, Sheldon Greer, Jonathan C. Cheng
Publikováno v:
Cancer cell. 6(2)
The frequent silencing of tumor suppressor genes by altered cytosine methylation and chromatin structural changes makes this process an attractive target for epigenetic therapy. Here we show that zebularine, a stable DNA cytosine methylation inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8309eb27e3dee85836bd4c34cdab221f
https://pubmed.ncbi.nlm.nih.gov/15324698
https://pubmed.ncbi.nlm.nih.gov/15324698
Autor:
Peter A. Jones, Cindy B. Matsen, Eric U. Selker, Jonathan C. Cheng, Felicidad A. Gonzales, Wei Ye, Victor E. Marquez, Sheldon Greer
Publikováno v:
Journal of the National Cancer Institute. 95(5)
Background: Gene silencing by abnormal methylation of promoter regions of regulatory genes is commonly associated with cancer. Silenced tumor suppressor genes are obvious targets for reactivation by methylation inhibitors such as 5-azacytidine (5-Aza
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d70b95d478b7d8cfb8c1352c9c8ad8
https://pubmed.ncbi.nlm.nih.gov/12618505
https://pubmed.ncbi.nlm.nih.gov/12618505
Publikováno v:
International journal of radiation oncology, biology, physics. 32(4)
Purpose : To extend our findings in previous radiation and biochemical studies with five rodent tumors, in which we used one and occasionally two or three irradiations. The extent of control of the EMT-6 mammary adenocarcinoma was determined using fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbbbd6f2790cea82b675aae6d2120f46
https://pubmed.ncbi.nlm.nih.gov/7607927
https://pubmed.ncbi.nlm.nih.gov/7607927
Autor:
Sheldon Greer, Janet Barletta
Publikováno v:
Antiviral research. 18(1)
Although several hypomethylating agents such as 5-azadeoxycytidine and 5-fluorodeoxycytidine have been shown to activate transcription after incorporation into viral or cellular DNA, agents which selectively affect the methylation status of virus-inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b0c76214f6d61e64ae0cf418d33534c
https://pubmed.ncbi.nlm.nih.gov/1384426
https://pubmed.ncbi.nlm.nih.gov/1384426
Publikováno v:
International journal of radiation oncology, biology, physics. 22(3)
5-Chlorodeoxycytidine (CldC), coadministered with modulators of pyrimidine metabolism, is an effective radiosensitizer of murine tumors. Past studies that utilized RIF-1 tumors in C3H mice and Lewis lung carcinoma (LLC) in BDF1 mice have been extende
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4973750186df68ee2d38ee77ea01ae11
https://pubmed.ncbi.nlm.nih.gov/1735688
https://pubmed.ncbi.nlm.nih.gov/1735688
Autor:
Sheldon Greer, Liliana M. Perez
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 12:1523-1527
5-Chloro-2'-deoxycytidine (CldC) + tetrahydrouridine (H4U) sensitizes mammalian cells (HEp-2, RIF-1, S-180) to X ray. This sensitization, as demonstrated previously with HEp-2 cells, is heightened when cells are pre-incubated with inhibitors of pyrim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ecbe6607f9ac2a84bd92ce797dbb614
https://doi.org/10.1016/0360-3016(86)90208-7
https://doi.org/10.1016/0360-3016(86)90208-7